Cogentis Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Cogentis Therapeutics's estimated annual revenue is currently $1.6M per year.
- Cogentis Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Cogentis Therapeutics has 10 Employees.
- Cogentis Therapeutics grew their employee count by -9% last year.
Cogentis Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Strategic Program Director | Reveal Email/Phone |
Cogentis Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is Cogentis Therapeutics?
Cogentis Therapeutics is an early stage biotechnology company with a mission to develop and commercialize an innovative disease-modifying therapeutic for dementias such as frontotemporal dementia (FTD) and Alzheimer’s disease (AD) to improve patients’ quality of life and reduce the burden of disease on their families, providers, and the overall healthcare system. Our immediate goal is to develop a peptide-based compound, CT-526, for FTD.
keywords:N/A
N/A
Total Funding
10
Number of Employees
$1.6M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Baltimore
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.9M | 10 | -9% | N/A |
#2 | $0.9M | 10 | 11% | N/A |
#3 | $0.9M | 10 | 0% | N/A |
#4 | $0.9M | 10 | 11% | N/A |
#5 | $1.2M | 10 | 43% | N/A |